Indirect Comparison of the Efficacy of Recombinant Factor Viii Fc Fusion Protein and Other Factor Viii Products for ProphylaxisModeling the Effect of Compliance

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1345
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Evaluation of the Toxicology and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein in Animals

Thrombosis Research
Hematology
2015English

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal in Vivo Efficacy but Exhibits Altered in Vitro Activity

PLoS ONE
Multidisciplinary
2014English

Who Should Be Liable for Funding Recombinant Factor VIII?

BMJ
1998English

Factor VIII Associated With Lipidic Nanoparticles Retains Efficacy in the Presence of Anti-Factor VIII Antibodies in Hemophilia a Mice

Biopharmaceutics and Drug Disposition
MedicinePharmacologyPharmaceutical Science
2016English

Different Impact of Factor VIII Products on Inhibitor Development?

Thrombosis Journal
Hematology
2016English

Studies on the Purification of Antihemophilic Factor (Factor VIII)

Journal of Clinical Investigation
Medicine
1969English

Combined Deficiency of Factor v and Factor VIII

2020English

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice

PLoS ONE
Multidisciplinary
2016English

Structural Basis for the Cooperative Interplay Between the Two Causative Gene Products of Combined Factor v and Factor VIII Deficiency

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy